Surrogate markers in antiangiogenesis clinical trials.


Journal Article (Review)

Novel antiangiogenic agents currently being developed may ultimately be more effective against solid tumours and less toxic than cytotoxic chemotherapy. As a result of the early clinical trials of angiogenesis inhibitors, investigators are beginning to appreciate the complexity of targeting angiogenesis and the realisation that developing clinically useful antiangiogenic therapy will be more challenging than originally thought. It is now apparent that new methods and surrogate markers to assess these agents' biological activity are crucial for their successful development. This review summarises the currently available clinical data on the development of surrogate markers of angiogenesis inhibitors.

Full Text

Duke Authors

Cited Authors

  • Davis, DW; McConkey, DJ; Abbruzzese, JL; Herbst, RS

Published Date

  • July 7, 2003

Published In

Volume / Issue

  • 89 / 1

Start / End Page

  • 8 - 14

PubMed ID

  • 12838293

Pubmed Central ID

  • 12838293

International Standard Serial Number (ISSN)

  • 0007-0920

Digital Object Identifier (DOI)

  • 10.1038/sj.bjc.6601035


  • eng

Conference Location

  • England